209 related articles for article (PubMed ID: 31277773)
21. Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review.
Shsm H; Fahmy UA; Alhakamy NA; Khairul-Asri MG; Fahmy O
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834547
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
23. Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.
McGregor BA; Sonpavde GP
Eur Urol Focus; 2020 Jan; 6(1):14-16. PubMed ID: 30910391
[TBL] [Abstract][Full Text] [Related]
24. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
25. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
26. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
27. [The role of immunooncology in the treatment of urothelial cancer].
Retz M; Tauber R; Horn T
Aktuelle Urol; 2017 Aug; 48(4):329-335. PubMed ID: 28591872
[TBL] [Abstract][Full Text] [Related]
28. New advances in genitourinary cancer: evidence gathered in 2014.
Suárez C; Puente J; Gallardo E; Méndez-Vidal MJ; Climent MA; León L; Olmos D; García del Muro X; González-Billalabeitia E; Grande E; Bellmunt J; Mellado B; Maroto P; González del Alba A
Cancer Metastasis Rev; 2015 Sep; 34(3):443-64. PubMed ID: 26227584
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
Marciscano AE; Madan RA
Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
[TBL] [Abstract][Full Text] [Related]
30. Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies.
Patel SH; Panian J; Bree K; Derweesh I; Millard F; Randall J; Mckay R
Eur Urol Focus; 2020 Jan; 6(1):17-25. PubMed ID: 31255618
[TBL] [Abstract][Full Text] [Related]
31. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review.
Trapani S; Manicone M; Sikokis A; D'Abbiero N; Salaroli F; Ceccon G; Buti S
Crit Rev Oncol Hematol; 2019 Oct; 142():9-15. PubMed ID: 31325712
[TBL] [Abstract][Full Text] [Related]
33. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
[TBL] [Abstract][Full Text] [Related]
36. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
[TBL] [Abstract][Full Text] [Related]
38. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
40. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Teo MY; Rosenberg JE
Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
